var title_f30_0_30720="Confidentiality agreement";
var content_f30_0_30720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Confidentiality agreement for adolescent health care",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 430px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Confidentiality in adolescent health care. ACOG educational bulletin #249. Int J Gynecol Obstet 1998; 63:295. Copyright &copy;1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30720=[""].join("\n");
var outline_f30_0_30720=null;
var title_f30_0_30721="Reactive arthritis (formerly Reiter syndrome)";
var content_f30_0_30721=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/0/30721/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30721/contributors\" id=\"au6352\">",
"       David T Yu, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/0/30721/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30721/contributors\" id=\"se174\">",
"       Joachim Sieper, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/0/30721/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30721/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/0/30721?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Reactive arthritis is a type of arthritis in which the joints become painful and swollen after an episode of infection. The infection might have been in the intestines, genitals, or the urinary tract.",
"    </p>",
"    <p>",
"     Reactive arthritis belongs to a family of arthritis conditions called spondyloarthritis (spondyloarthropathies or spondyloarthritides). This family of arthritis disorders includes ankylosing spondylitis; undifferentiated spondyloarthritis; and arthritis associated with psoriasis (psoriatic arthritis), Crohn's disease, and ulcerative colitis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"      \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"      \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some clinicians use the term &ldquo;Reiter syndrome&rdquo; instead of &ldquo;reactive arthritis.&rdquo;",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Two types of bacteria are responsible for most cases of reactive arthritis:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bacteria that cause bowel infections &mdash; These include the bacterial species Salmonella, Shigella, Campylobacter, and Yersinia. These bacteria often cause diarrhea, which can last up to one month. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"        \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Bacteria that cause genital infections &mdash; These include Chlamydia trachomatis, a sexually transmitted infection. Chlamydia can cause pelvic pain, burning with urination, and a pus-like or watery vaginal or penile discharge. Some people have no symptoms with their infection. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"        \"Patient information: Chlamydia (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     The risk factors are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A preceding infection &mdash; As discussed above, predisposing infections are typically either foodborne diseases or sexually transmitted diseases.",
"      </li>",
"      <li>",
"       Genetic predisposition &mdash; Genetic risk is associated with having a particular variant of the HLA-B gene known as HLA-B27.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Typical symptoms of reactive arthritis include joint pain and swelling that develops suddenly, usually one to four weeks after an episode of infection. Frequently, the pain and swelling involve a small number of joints (three or less), typically including the knee, ankle, or joints of the feet. Some patients have tendonitis affecting the Achilles tendon, behind the ankle, or the plantar fascia, on the sole of the foot where it attaches to the heel.",
"    </p>",
"    <p>",
"     Conjunctivitis (inflammation of the covering of the eyes) can also occur in people with reactive arthritis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Diagnosis depends first on the distribution and location of pain and swelling of the extremities and, secondly, on a history of having had symptoms of diarrhea or of a sexually transmitted disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      REACTIVE ARTHRITIS TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics may be used to treat an active genital infection. However, there is no convincing evidence that antibiotics will improve joint pain or will shorten the course of reactive arthritis after the joint pain has developed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Nonsteroidal antiinflammatory drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, naproxen, or indomethacin are usually recommended to reduce joint pain and swelling. Relatively large doses of an NSAID may be needed on a regular basis for up to two weeks to determine if the NSAID is effective. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Other treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you do not improve with NSAIDs, your clinician may recommend a glucocorticoid (also called a steroid) injection into the joint. Additional treatment with glucocorticoids (taken by mouth or as an injection) might be necessary for a short period if you have severe pain or joint swelling.",
"    </p>",
"    <p>",
"     Another medication, such as one of the disease modifying antirheumatic drugs (DMARDs; eg, sulfasalazine or methotrexate), or a medication that interferes with the action of tumor necrosis factor (TNF) (a TNF inhibitor or blocker such as etanercept, infliximab, or adalimumab) may be recommended if your symptoms do not improve with NSAIDs or with glucocorticoid treatment. In this case, you should see a specialist in inflammatory joint diseases (a rheumatologist) to confirm that your symptoms are caused by reactive arthritis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=see_link\">",
"      \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Eye treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eye inflammation can occur in people with reactive arthritis and is sometimes treated with glucocorticoid eye drops. If you develop eye pain or blurry vision, you should see an ophthalmologist to determine if your symptoms are due to conjunctivitis or a more serious eye problem such as inflammation of the iris (called iritis or anterior uveitis). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=see_link\">",
"      \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHEN WILL I GET BETTER?",
"     </span>",
"    </p>",
"    <p>",
"     Most people with reactive arthritis have a mild course of joint pain that resolves spontaneously and that never comes back. In some people, the disease will intermittently cause symptoms. In others, the disease is persistent.",
"    </p>",
"    <p>",
"     If your back becomes painful and stiff and does not improve with time, reactive arthritis may have developed into a spondyloarthropathy. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784909062\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1942494\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/0/29698?source=see_link\">",
"      Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/7/8307?source=see_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/15/15601?source=see_link\">",
"      Patient information: Osteomyelitis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1942511\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/39/10869?source=see_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/30/29156?source=see_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/11/17586?source=see_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/51/12090?source=see_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/27/33210?source=see_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/16/23817?source=see_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Spondylitis Association of America",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.spondylitis.org/\">",
"        www.spondylitis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nih.gov/niams/\">",
"        www.nih.gov/niams/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/0/30721/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/0/30721?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30721/abstract/1\">",
"      Healy PJ, Helliwell PS. Classification of the spondyloarthropathies. Curr Opin Rheumatol 2005; 17:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30721/abstract/2\">",
"      D'Agostino MA, Olivieri I. Enthesitis. Best Pract Res Clin Rheumatol 2006; 20:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30721/abstract/3\">",
"      Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol 2005; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30721/abstract/4\">",
"      Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. Arthritis Rheum 2002; 46:319.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_0_30721=[""].join("\n");
var outline_f30_0_30721=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           REACTIVE ARTHRITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REACTIVE ARTHRITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           REACTIVE ARTHRITIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           REACTIVE ARTHRITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           REACTIVE ARTHRITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           REACTIVE ARTHRITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHEN WILL I GET BETTER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_0_30722="Powers ratio for cervical spine";
var content_f30_0_30722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Powers ratio for cervical spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30722=[""].join("\n");
var outline_f30_0_30722=null;
var title_f30_0_30723="Prednisolone (ophthalmic): Drug information";
var content_f30_0_30723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/13/43220?source=see_link\">",
"    see \"Prednisolone (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37650?source=see_link\">",
"    see \"Prednisolone (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnipred&trade;;",
"     </li>",
"     <li>",
"      Pred Forte&reg;;",
"     </li>",
"     <li>",
"      Pred Mild&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diopred&reg;;",
"     </li>",
"     <li>",
"      Ophtho-Tate&reg;;",
"     </li>",
"     <li>",
"      Pred Forte&reg;;",
"     </li>",
"     <li>",
"      Pred Mild&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9518605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Conjunctivitis:",
"     </b>",
"     Ophthalmic (suspension/solution): Instill 1-2 drops in the eye 2-4 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9505645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37650?source=see_link\">",
"      see \"Prednisolone (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Conjunctivitis:",
"     </b>",
"     Ophthalmic (suspension/solution): Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9774998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9506894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium phosphate [drops]: 1% (5 mL [DSC], 10 mL, 15 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as acetate [drops]: 1% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnipred&trade;: 1% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred Forte&reg;: 1% (1 mL, 5 mL, 10 mL, 15 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pred Mild&reg;: 0.12% (5 mL, 10 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of palpebral and bulbar conjunctivitis; corneal injury from chemical, radiation, thermal burns, or foreign body penetration; steroid-responsive inflammatory ophthalmic diseases",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PrednisoLONE may be confused with predniSONE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Conjunctival hyperemia, conjunctivitis, corneal ulcers, delayed wound healing, glaucoma, intraocular pressure increased, keratitis, loss of accommodation, optic nerve damage, mydriasis, posterior subcapsular cataract formation, ptosis, secondary ocular infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednisolone or any component of the formulation; viral diseases of the cornea and conjunctiva (eg, acute superficial herpes simplex keratitis); mycobacterial or fungal infections of the eye",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corneal thinning: Various ophthalmic disorders, as well as prolonged use of corticosteroids, may result in corneal and scleral thinning. Continued use in a patient with thinning may result in rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP) and glaucoma; damage to the optic nerve (not indicated for treatment of optic neuritis); and defects in visual acuity and fields of vision. Monitor IOP in any patient receiving treatment for &ge;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), or prolong or exacerbate viral infections. Corticosteroids should not be used to treat ocular herpes simplex. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not effective in Sjogren's keratoconjunctivitis or mustard gas keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9505562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ophthalmic prednisolone was shown to be teratogenic in animal studies The amount of prednisolone available systemically following topical application of the ophthalmic drops is not known; refer to the PrednisoLONE, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9887317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of prednisolone available systemically following topical application of the ophthalmic drops is not known; refer to the PrednisoLONE, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9506896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (PrednisoLONE Sodium Phosphate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $59.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Omnipred Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (5 mL): $82.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pred Forte Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (5 mL): $55.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pred Mild Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.12% (5 mL): $37.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (PrednisoLONE Acetate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $23.10",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adelone (GR);",
"     </li>",
"     <li>",
"      Econopred (MY);",
"     </li>",
"     <li>",
"      Econopred Plus (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Frisolona (PT);",
"     </li>",
"     <li>",
"      Frisolona Forte (PT);",
"     </li>",
"     <li>",
"      Ilocet (PH);",
"     </li>",
"     <li>",
"      Inflanefran (DE);",
"     </li>",
"     <li>",
"      Ocu-Pred (VE);",
"     </li>",
"     <li>",
"      Pred Forte (BE, BR, CH, CL, CN, FI, GB, HK, IE, IL, KP, NL, NZ, PH, SG, TH, TR, TW, ZA);",
"     </li>",
"     <li>",
"      Pred Mild (BR, HK, MY, NZ, PH, SG, TH, ZA);",
"     </li>",
"     <li>",
"      Predmet (IN);",
"     </li>",
"     <li>",
"      Prednefrin (CO, PE);",
"     </li>",
"     <li>",
"      Prednefrin Forte (AU, PE, VE);",
"     </li>",
"     <li>",
"      Predni-Ophtal (DE);",
"     </li>",
"     <li>",
"      Predni-POS (CZ);",
"     </li>",
"     <li>",
"      Predniocil (PT);",
"     </li>",
"     <li>",
"      Predon (MY);",
"     </li>",
"     <li>",
"      Predsol (GB);",
"     </li>",
"     <li>",
"      Predsol-Forte (DO, HN);",
"     </li>",
"     <li>",
"      Sophipren Ofteno (CN, CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ultracortenol (AR, PY, SE, TW);",
"     </li>",
"     <li>",
"      Vistapred (PH)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9912 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30723=[""].join("\n");
var outline_f30_0_30723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505541\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505548\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518605\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505646\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505645\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9774998\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506894\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505550\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505551\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505496\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505603\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505586\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505587\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505606\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505562\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887317\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506896\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992811\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9912|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/13/43220?source=related_link\">",
"      Prednisolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37650?source=related_link\">",
"      Prednisolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40376?source=related_link\">",
"      Prednisolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/12/29894?source=related_link\">",
"      Prednisolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/54/1896?source=related_link\">",
"      Prednisolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_0_30724="Bromazepam: Patient drug information";
var content_f30_0_30724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bromazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/17/17686?source=see_link\">",
"     see \"Bromazepam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bromazepam&reg;;",
"     </li>",
"     <li>",
"      Lectopam&reg;;",
"     </li>",
"     <li>",
"      Mylan-Bromazepam;",
"     </li>",
"     <li>",
"      Novo-Bromazepam;",
"     </li>",
"     <li>",
"      Nu-Bromazepam;",
"     </li>",
"     <li>",
"      PRO-Doc Limitee Bromazepam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bromazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, very bad liver disease, very bad lung disease, myasthenia gravis, or sleep apnea.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11254 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30724=[""].join("\n");
var outline_f30_0_30724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142412\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263327\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014766\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014765\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014770\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014771\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014773\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014768\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014769\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014774\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014775\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/17/17686?source=related_link\">",
"      Bromazepam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_0_30725="M mode echo parasternal long axis";
var content_f30_0_30725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiographic examination of the heart in the parasternal long axis position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A diagrammatic representation of the long axis of the heart is seen on top; the transducer (T) sits on the anterior chest wall in the precordial parasternal window and the beam is swept from apex to base. The appearance of the echogram at three beam positions on the diagram is designated by the arrows connecting the diagram to the echogram which displays the cardiac structures that are imaged by the beam (bottom panel). A pericardial effusion (PE) is seen as an echo-free space posterior to the left ventricle. This space diminishes and finally disappears as the base of the heart is approached because the pericardium reflects at mid atrium.",
"    <div class=\"footnotes\">",
"     Ao: aorta; LA: left atrium; LV: left ventricle; MV: mitral valve; P: pericardium; PE: pericardial effusion; RV: right ventricle; Ant RVW: anterior RV wall; Post LVW: posterior LV wall.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30725=[""].join("\n");
var outline_f30_0_30725=null;
var title_f30_0_30726="Guaifenesin and dextromethorphan: Drug information";
var content_f30_0_30726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/7/40052?source=see_link\">",
"    see \"Guaifenesin and dextromethorphan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/46/17125?source=see_link\">",
"    see \"Guaifenesin and dextromethorphan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cheracol&reg; D [OTC];",
"     </li>",
"     <li>",
"      Cheracol&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Coricidin HBP&reg; Chest Congestion and Cough [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin-DM DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Double Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Fenesin DM IR [OTC];",
"     </li>",
"     <li>",
"      Guaicon DMS [OTC];",
"     </li>",
"     <li>",
"      Iophen DM-NR [OTC];",
"     </li>",
"     <li>",
"      Kolephrin&reg; GG/DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid&rsquo;s Cough [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin DM [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Robafen DM Clear [OTC];",
"     </li>",
"     <li>",
"      Robafen DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Maximum Strength Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Peak Cold Sugar-Free Cough + Chest Congestion DM [OTC];",
"     </li>",
"     <li>",
"      Safe Tussin&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Senior [OTC];",
"     </li>",
"     <li>",
"      Silexin [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM DAS [OTC];",
"     </li>",
"     <li>",
"      Siltussin DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44E [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control DM [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough &amp; Chest Congestion [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Pediatric Formula 44E [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil DM E;",
"     </li>",
"     <li>",
"      Benylin&reg; DM-E",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Cough Preparation;",
"     </li>",
"     <li>",
"      Expectorant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cough (antitussive/expectorant):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      General dosing guidelines:",
"     </i>",
"     Guaifenesin 200-400 mg and dextromethorphan 10-20 mg every 4 hours (maximum dose: Guaifenesin 2400 mg and dextromethorphan 120 mg per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Product-specific labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; DM: 1-2 tablets every 12 hours (maximum: 4 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; 44E: 15 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Pediatric Formula 44E: 30 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/46/17125?source=see_link\">",
"      see \"Guaifenesin and dextromethorphan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cough (antitussive/expectorant):",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2-6 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      General dosing guidelines:",
"     </i>",
"     Guaifenesin 50-100 mg and dextromethorphan 2.5-5 mg every 4 hours (maximum dose: Guaifenesin 600 mg and dextromethorphan 30 mg per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Product-specific labeling:",
"     </i>",
"     Vicks&reg; Pediatric Formula 44E: 7.5 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      General dosing guidelines:",
"     </i>",
"     Guaifenesin 100-200 mg and dextromethorphan 5-10 mg every 4 hours (maximum dose: Guaifenesin 1200 mg and dextromethorphan 60 mg per day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Product-specific labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vicks&reg; 44E: 7.5 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vicks&reg; Pediatric Formula 44E: 15 mL every 4 hours (maximum: 6 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenesin DM IR: Guaifenesin 400 mg and dextromethorphan hydrobromide 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade; DM: Guaifenesin 400 mg and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coricidin HBP&reg; Chest Congestion and Cough: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid&rsquo;s Cough Mini-Melts&trade;: Guaifenesin 100 mg and dextromethorphan hydrobromide 5 mg per packet (12s) [contains magnesium 6 mg/pack, phenylalanine 2 mg/packet, sodium 3 mg/packet; orange cr&egrave;me flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; DM Maximum Strength: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Double Tussin DM: Guaifenesin 300 mg and dextromethorphan hydrobromide 20  mg per 5 mL (120 mL, 480 mL) [dye free, ethanol free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iophen DM-NR: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (480 mL) [contains propylene glycol, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kolephrin&reg; GG/DM: Guaifenesin 150 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [ethanol free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid&rsquo;s Cough: Guaifenesin 100 mg and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL) [contains propylene glycol, sodium 3 mg/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Safe Tussin&reg; DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 15 mg per 5 mL (120 mL) [contains benzoic acid, phenylalanine 4.2 mg/5 mL, and propylene glycol; orange and mint flavors]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Senior: Guaifenesin 200 mg and dextromethorphan hydrobromide 15 mg per 5 mL (120 mL) [ethanol free, sodium free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; 44E: Guaifenesin 200 mg and dextromethorphan hydrobromide 20 mg per 15 mL (120 mL, 235 mL) [contains ethanol, sodium 31 mg/15 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Mucus Control DM: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 15 mL (295 mL) [contains propylene glycol, sodium 25 mg/15 mL, sodium benzoate; citrus blend flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Nature Fusion&trade; Cough &amp; Chest Congestion: Guaifenesin 200 mg and dextromethorphan hydrobromide 20 mg per 30 mL (236 mL) [dye free, ethanol free, gluten free; contains propylene glycol, sodium 36 mg/30 mL; honey flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Pediatric Formula 44E: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 15 mL (120 mL) [ethanol free; contains sodium 30 mg/15 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (5 mL, 10 mL, 120 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cheracol&reg; D: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 180 mL) [contains benzoic acid, ethanol 4.75%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cheracol&reg; Plus: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [contains benzoic acid, ethanol 4.75%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin-DM DAS-Na: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin-DM DAS-Na Maximum Strength: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Guaicon DMS: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (10 mL) [ethanol free, sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Tussin DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (118 mL, 237 mL, 473 mL) [ethanol free, contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL, 480 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen DM Clear: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Cough + Chest Congestion DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL ( 120 mL, 240 mL) [contains menthol, propylene glycol, sodium 7 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Sugar-Free Cough + Chest Congestion DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [sugar free; contains  propylene glycol, sodium 3 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Peak Cold Maximum Strength Cough + Chest Congestion DM: Guaifenesin 200 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL) [contains menthol, propylene glycol, sodium 5 mg/5 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silexin: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (45 mL) [ethanol free, sugar free)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin DM: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 240 mL, 480 mL) [strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin DM DAS: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL) [dye free, ethanol free, sugar free; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Guaifenesin 1000 mg and dextromethorphan hydrobromide 60 mg; guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silexin: Guaifenesin 100 mg and dextromethorphan hydrobromide 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; DM: Guaifenesin 600 mg and dextromethorphan hydrobromide 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; DM Maximum Strength: Guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral [scored]: Guaifenesin 1200 mg and dextromethorphan hydrobromide 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with water. Do not crush or chew extended release or long acting formulations.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary control of cough due to minor throat and bronchial irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benylin&reg; may be confused with Benadryl&reg;, Ventolin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin, dextromethorphan, or any component of the formulation; use with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are sedated, debilitated or confined to a supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in atopic children. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC), notify healthcare provider if symptoms do not improve within 7 days, or are accompanied by fever, rash, or persistent headache.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13360258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F177715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Alka-Seltzer Plus Mucus &amp; Cong Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg (20): $5.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Broncotron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg/5 mL (118 mL): $10.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Cheracol-D Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg/5 mL (120 mL): $7.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Diabetic Tussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (118 mL): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Diabetic Tussin Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg/5 mL (118 mL): $4.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Double-Tussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-300 mg/5 mL (240 mL): $7.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (G-Tron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg/5 mL (474 mL): $15.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mucinex Cough Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-100 mg/5 mL (118 mL): $7.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mucinex Fast-Max DM Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-400 mg/20 mL (177 mL): $10.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cold Cough+ Chest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-100 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough+ Chest Max St Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg/5 mL (118 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Cough/Chest DM Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg/5 mL (118 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin To Go Cgh/Chest DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (10 mL): $0.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Safe Tussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (120 mL): $4.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Scot-Tussin Senior Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-200 mg/5 mL (118.3 mL): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tolu-Sed DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (120 mL): $2.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Trispec DMX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-125 mg/5 mL (120 mL): $13.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks DayQuil Mucus Control DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg/15 mL (354 mL): $7.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks Nature Fusion Congest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-200 mg/30 mL (236 mL): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Wal-Tussin Cough/Chest DM Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200 mg/5 mL (118 mL): $4.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Mucinex Cough For Kids Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-100 mg (12): $7.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robafen DM Cough Clear Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (118 mL): $2.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (237 mL): $7.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin DM Sugar Free Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin Peak Cold DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Vicks Formula 44 Chesty Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-200 mg/15 mL (177 mL): $6.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Zyncof Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-400 mg/5 mL (120 mL): $13.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucinex DM Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-1200 mg (14): $12.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucinex DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-600 mg (20): $11.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenesin DM IR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-400 mg (100): $13.20",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bre-A-Col (MX);",
"     </li>",
"     <li>",
"      Cheracol D (MX);",
"     </li>",
"     <li>",
"      Debequin C (MX);",
"     </li>",
"     <li>",
"      Dequin (MX);",
"     </li>",
"     <li>",
"      Dexometorfano-Guaifenesina (MX);",
"     </li>",
"     <li>",
"      Dimacol (MX);",
"     </li>",
"     <li>",
"      Exiadol (MX);",
"     </li>",
"     <li>",
"      Megal (MX);",
"     </li>",
"     <li>",
"      Robitussin DM (MX);",
"     </li>",
"     <li>",
"      Tukol D (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Guaifenesin is thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing phlegm viscosity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dextromethorphan is a chemical relative of morphine lacking narcotic properties except in overdose; controls cough by depressing the medullary cough center",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8505 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-84E1ECB1DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30726=[""].join("\n");
var outline_f30_0_30726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177719\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177720\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177736\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177723\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177731\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177724\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177707\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177694\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177710\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177709\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177743\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177734\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177713\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177698\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177702\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177714\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13360258\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177715\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524625\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177716\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177697\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177712\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8505|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/7/40052?source=related_link\">",
"      Guaifenesin and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/46/17125?source=related_link\">",
"      Guaifenesin and dextromethorphan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_0_30727="Starting position for straight leg raise";
var content_f30_0_30727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55455%7EEM%2F64621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55455%7EEM%2F64621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Starting position for straight leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Straight leg raise for patella fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform the straight leg raise, elevate the&nbsp;leg to 20 to 25 degrees, hold for a few seconds, and return to the starting position. Repeat for a total of 10 repetitions per set.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Blount, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30727=[""].join("\n");
var outline_f30_0_30727=null;
var title_f30_0_30728="Contact dermatitis drug";
var content_f30_0_30728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77613%7EDERM%2F70264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77613%7EDERM%2F70264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis due to neomycin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This contact dermatitis is secondary to neomycin in ear drops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis due to nickel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nickel in earrings caused this dermatitis on the ear lobe and neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30728=[""].join("\n");
var outline_f30_0_30728=null;
var title_f30_0_30729="Port wine stain - V2 infant";
var content_f30_0_30729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59124%7EDERM%2F73978%7EDERM%2F54078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59124%7EDERM%2F73978%7EDERM%2F54078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain in the V2 distribution is present on the face of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain, represented by an erythematous patch, is present in the V2 distribution on the face of this child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port wine stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A port wine stain, manifesting as an erythematous patch with multiple small, vascular papules, is present on the leg of this adult.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30729=[""].join("\n");
var outline_f30_0_30729=null;
var title_f30_0_30730="Drug prescribing for older adults";
var content_f30_0_30730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug prescribing for older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Paula A Rochon, MD, MPH, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/0/30730/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/0/30730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimizing drug therapy is an essential part of caring for an older person. The process of prescribing a medication is complex and includes: deciding that a drug is indicated, choosing the best drug, determining a dose and schedule appropriate for the patient's physiologic status, monitoring for effectiveness and toxicity, educating the patient about expected side effects, and indications for seeking consultation.",
"   </p>",
"   <p>",
"    Avoidable adverse drug events are the serious consequences of inappropriate drug prescribing. The possibility of an adverse drug event should always be borne in mind when evaluating an older adult individual; any new symptom should be considered drug-related until proven otherwise.",
"   </p>",
"   <p>",
"    Prescribing for older patients presents unique challenges. Premarketing drug trials often exclude geriatric patients and approved doses may not be appropriate for older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/1\">",
"     1",
"    </a>",
"    ]. Many medications need to be used with special caution because of age-related changes in pharmacokinetics (ie, absorption, distribution, metabolism, and excretion) and pharmacodynamics (the physiologic effects of the drug).",
"   </p>",
"   <p>",
"    Particular care must be taken in determining drug dosages when prescribing for older adults. An increased volume of distribution may result from the proportional increase in body fat relative to skeletal muscle with aging. Decreased drug clearance may result from the natural decline in renal function with age, even in the absence of renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/2\">",
"     2",
"    </a>",
"    ]. Larger drug storage reservoirs and decreased clearance prolong drug half-lives and lead to increased plasma drug concentrations in older people.",
"   </p>",
"   <p>",
"    As examples, the volume of distribution for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    is increased, and the clearance rate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is reduced, in older adults. The same dose of either medication would lead to higher plasma concentrations in an older, compared to younger, patient. Also, from the pharmacodynamic perspective, increasing age may result in an increased sensitivity to the effects of certain drugs, including benzodiazepines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/3-6\">",
"     3-6",
"    </a>",
"    ] and opioids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A stepwise approach to optimized prescribing of drug therapy for older adults will be reviewed here. Drug treatments for specific conditions in the older population are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICATION USE BY OLDER ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications (prescription, over-the-counter, and herbal preparations) are widely used by older adults. A survey in the United States of a representative sampling of 3005 community dwelling adults (aged 57 through 85 years) was conducted by in-home interviews and use of medication logs between 2005 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/8\">",
"     8",
"    </a>",
"    ]. At least one prescription medication was used by 81 percent. Five or more prescription medications were used by 29 percent of the overall survey population and by 36 percent of people aged 75 to 85 years. Forty-six percent of prescription users also took at least one over-the- counter medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Herbal and dietary supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of herbal or dietary supplements (eg, ginseng, ginkgo biloba extract, and glucosamine) by older adults has been increasing, from 14 percent in older women in 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/9\">",
"     9",
"    </a>",
"    ] to 26 to 27 percent in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and 49 percent in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/8\">",
"     8",
"    </a>",
"    ]. One study in over 3000 ambulatory adults 75 years of age or older in four states in the US found that almost three-quarters used at least one prescription drug and one dietary supplement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/12\">",
"     12",
"    </a>",
"    ]. Often, clinicians do not question patients about use of herbal medicines and patients do not routinely volunteer this information. In one US survey, three-quarters of respondents aged 18 years and older reported that they did not inform their clinician that they were using unconventional medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herbal medicines may interact with prescribed drug therapies and lead to adverse events, underscoring the importance of routinely questioning patients about the use of unconventional therapies. Examples of herbal-drug therapy interactions include ginkgo biloba extract taken with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , causing an increased risk of bleeding, and St. John's wort taken with serotonin-reuptake inhibitors, increasing the risk of serotonin syndrome in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/14\">",
"     14",
"    </a>",
"    ]. A study of the use of 22 supplements in a survey of 369 patients aged 60 to 99 years found potential interactions between supplements and medications for 10 of the 22 supplements surveyed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Herb-drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many older adults receive their information about herbal products from the internet. Eighty percent of 338 retail web sites identified in a search of the eight most widely used herbal supplements (ginkgo biloba, St. John's wort, echinacea, ginseng, garlic, saw palmetto, kava, and valerian root) made at least one health claim suggesting that the therapy could treat, prevent, or even cure specific conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     QUALITY OF DRUG PRESCRIBING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple dimensions contribute to the appropriateness and overall quality of drug prescribing. These include avoidance of inappropriate medications, appropriate utilization of indicated medications, monitoring for side effects and drug levels, avoidance of drug-drug interactions, and involvement of the patient and integration of patient values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indicators of the quality prescribing often focus on one or some of these dimensions, but rarely on all. Furthermore, the predictive value of these measures of \"quality of prescribing\" in determining important long-term outcomes of care have not been determined. Approaches to improve inappropriate prescribing in older adults include educational interventions, computerized order entry and decision support, multidisciplinary team care led by geriatricians or non-geriatricians, clinical pharmacists, and multifaceted approaches. Available data for these interventions generally show significant improvements in inappropriate prescribing but mixed results for health outcomes or costs; some interventions had little or negative impact on health outcomes or costs whereas as others had a positive impact on health outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18186995\">",
"    <span class=\"h1\">",
"     POLYPHARMACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polypharmacy is defined simply as the use of multiple medications by a patient. The precise minimum number of medications used to define &ldquo;polypharmacy&rdquo; is variable, but generally ranges from 5 to 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/18\">",
"     18",
"    </a>",
"    ]. While polypharmacy most commonly refers to prescribed medications, it is important to also consider the number of over-the-counter and",
"    <span class=\"nowrap\">",
"     herbal/supplements",
"    </span>",
"    used.",
"   </p>",
"   <p>",
"    The issue of polypharmacy is of particular concern in older people who, compared to younger individuals, tend to have more disease conditions for which therapies are prescribed. It has been estimated that 20 percent of Medicare beneficiaries have five or more chronic conditions and 50 percent receive five or more medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of greater numbers of drug therapies has been independently associated with an increased risk for an adverse drug event, irrespective of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/20\">",
"     20",
"    </a>",
"    ]. There are multiple reasons why older adults are especially impacted by polypharmacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older individuals are at greater risk for adverse drug events due to metabolic changes and decreased drug clearance associated with aging; this risk is compounded by increasing numbers of drugs used.",
"     </li>",
"     <li>",
"      Polypharmacy increases the potential for drug-drug interactions.",
"     </li>",
"     <li>",
"      Polypharmacy was an independent risk factor for hip fractures in older adults in one case-control study, although the number of drugs may have been an indicator of higher likelihood of exposure to specific types of drugs associated with falls (eg, CNS active drugs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polypharmacy increases the possibility of &ldquo;prescribing cascades&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/22\">",
"       22",
"      </a>",
"      ]. A prescribing cascade develops when an adverse drug event is misinterpreted as a new medical condition and additional drug therapy is then prescribed to treat this medical condition. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prescribing cascades'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of multiple medications can lead to problems with medication adherence, compounded by visual or cognitive compromise in many older adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A balance is required between over- and underprescribing. Multiple medications are often required to manage clinically complex older adults. Clinicians are often challenged with the need to match the complex needs of their older patients with those of disease-specific clinical practice guidelines. For a hypothetical older female patient with chronic obstructive pulmonary disease, type 2 diabetes, osteoporosis, hypertension and osteoarthritis, clinical practice guidelines would recommend prescribing 12 medications for this individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more systematic approach is required to guide the tailoring of medication regimens to the needs of individuals. One important principle is to match the medication regimen to the patient&rsquo;s condition and goals of care. This includes a careful consideration of the medications that should be discontinued or substituted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/24\">",
"     24",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef51353 \" href=\"mobipreview.htm?30/2/30765\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is particularly important to reconsider medication appropriateness late in life. A model for appropriate prescribing for patients late in life has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/25\">",
"     25",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef64079 \" href=\"mobipreview.htm?11/22/11627\">",
"     table 2",
"    </a>",
"    ). The process considers the patients&rsquo; remaining life expectancy and the goals of care in reviewing the need for existing medications and in making new prescribing decisions. For example, if a patient&rsquo;s life expectancy is short and the goals of care are palliative then prescribing a prophylatic medication requiring several years to realize a benefit may not be considered appropriate. This is increasingly being recognized as an important consideration when managing individuals with advanced dementia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/26\">",
"     26",
"    </a>",
"    ]. Additionally, therapeutic medications (eg, antibiotics for pneumonia) may not increase comfort or quality of life when palliative care is the objective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INAPPROPRIATE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various criteria have been developed by expert panels in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/28\">",
"     28",
"    </a>",
"    ] and in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/29-34\">",
"     29-34",
"    </a>",
"    ] to assess the quality of prescribing practices and medication use in older adult individuals. The most widely used criteria for inappropriate medications are the Beers criteria. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Beers criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In another approach, a Drug Burden Index has been modelled incorporating drugs with anticholinergic or sedative effects, total number of medications, and daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. An increased drug burden for anticholinergic and sedative medications was associated with impaired performance on mobility and cognitive testing in high-functioning community-based older adults. Total number of medications was not associated with impaired performance when sedatives and anticholinergics were excluded. A high Drug Burden Index has been correlated with increased risk for functional decline in community dwellers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/36\">",
"     36",
"    </a>",
"    ] and with increased risk of falls in residents in long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Anticholinergic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic medications are associated with multiple adverse effects to which older individuals are particularly susceptible. These adverse effects include memory impairment, confusion, hallucinations, dry mouth, blurred vision, constipation, nausea, urinary retention, impaired sweating, and tachycardia. Anticholinergics can precipitate an acute glaucoma episode in patients with narrow angle glaucoma and acute urinary retention in patients with benign prostatic hypertrophy. In a population study of 6912 men and women 65 years and older, those taking anticholinergic drugs were at increased risk for cognitive decline and dementia and risk decreased with medication discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/38\">",
"     38",
"    </a>",
"    ]. In another population of 13,004 individuals aged 65 and older, use of anticholinergic medications was also shown to be associated with greater decline in cognition as measured by the Mini-Mental State Examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, anticholinergic medication use was associated with increased mortality over a two year period after adjustment for multiple factors, including comorbid health conditions.",
"   </p>",
"   <p>",
"    A scale of risk for adverse events related to specific drugs with anticholinergic properties has been developed and prospectively validated in a population primarily composed of older male patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/40\">",
"     40",
"    </a>",
"    ], although its utility in clinical practice has not been determined. A higher anticholinergic risk score correlated with risk for both central (falls, dizziness, confusion) and peripheral (dry mouth, dry eyes, constipation) adverse events (",
"    <a class=\"graphic graphic_table graphicRef57410 \" href=\"mobipreview.htm?41/32/42508\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A study measured the in vitro anticholinergic activity (AA) of 107 medications commonly used in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/41\">",
"     41",
"    </a>",
"    ]. At usual doses, AA was most significantly elevated for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/6/27749?source=see_link\">",
"     dicyclomine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , L-hyoscyamine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    . AA also was increased for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    . It should be noted, however, that higher doses of an agent with relatively low or moderate AA can produce significant AA effects. Additionally, the cumulative effects of more than one agent with low AA can produce significant AA effects.",
"   </p>",
"   <p>",
"    Alternative drugs with lower AA are available in many classes represented by these drugs. However, adverse drug reactions other than AA should also be taken into account in weighing the clinical benefits of possible substitutions (eg dyskinesias and sedation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Beers criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Beers criteria, initially developed by an expert consensus panel in 1991 to target nursing home residents, are the most widely-cited criteria used to assess inappropriate drug prescribing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/29\">",
"     29",
"    </a>",
"    ]. The panel produced a list of medications considered inappropriate for older patients, either because of ineffectiveness or high risk for adverse events.",
"   </p>",
"   <p>",
"    The original Beers criteria have been revised in 1997, 2003, and most recently in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/30,31,42\">",
"     30,31,42",
"    </a>",
"    ]. The 2012 revised",
"    <a class=\"external\" href=\"file://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2012\">",
"     Beers criteria",
"    </a>",
"    are available through the American Geriatrics Society website. The criteria include 53 medications designated in one of three categories: those that should always be avoided (eg, barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ); those that are potentially inappropriate in older adults with particular health conditions or syndromes; and those that should be used with caution. New additions to the 34 potentially-inappropriate medications include sliding scale insulin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , and megestrol. Thiazolidinediones should be avoided in patients with heart failure, and selective serotonin reuptake inhibitors (SSRIs) in patients with falls and fractures.",
"   </p>",
"   <p>",
"    Several studies, using older versions of the Beers criteria, have identified that use of drugs identified as &ldquo;inappropriate&rdquo; was widespread in the United States, Canada, and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the inappropriate drug therapies identified on the Beers list are available as over-the-counter products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/46\">",
"     46",
"    </a>",
"    ]. This reinforces the need to always consider over-the-counter drug therapies when reviewing a patient's medications and to educate individuals on potential problems that can arise from the use of over-the-counter preparations.",
"   </p>",
"   <p>",
"    The Beer's criteria are increasingly being used to monitor quality of care for older adults. The validity of these consensus-derived criteria in predicting adverse outcomes therefore is becoming increasingly more important. Studies of earlier versions of the Beers criteria did predict adverse outcomes but that some medications not on the earlier criteria correlated more closely with adverse outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the 1996 Medical Expenditure Panel survey showed that risks of hospitalization and death were greater for nursing home patients who had been prescribed medications defined as potentially inappropriate by the 2003 combined Beers criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of 18 retrospective cohort studies found that for patients &gt;65 years old in the community setting, inappropriate medication use (defined by Beers criteria 1991, 1997, and 2003) was associated with increased hospitalization rates but not mortality; for patients in the nursing home setting, the relationship between inappropriate medications and hospitalization rates was inconclusive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study that used electronic data to survey adverse drug events associated with emergency department visits for patients &ge; 65 years of age found that drugs meeting Beers criteria for always potentially inappropriate accounted for 3.6 percent (95% CI 2.8-4.5 percent) of the estimated 178,000 visits [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/49\">",
"       49",
"      </a>",
"      ]. Three medications not on the Beers list (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , and insulin) accounted for 33.3 percent (95% CI 27.8-38.7 percent) of the visits, and medications in the general class of anticoagulants or antiplatelet agents, antidiabetic agents, and narrow therapeutic index agents accounted for nearly half of all visits, though were prescribed in only 9.4 percent of patients seen.",
"     </li>",
"     <li>",
"      Similar methodology was used by the same group to evaluate adverse drug events (ADEs) resulting in emergency hospitalizations among older Americans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/50\">",
"       50",
"      </a>",
"      ]. Four types of medication (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , insulin, oral antiplatelet agents, and oral hypoglycemics) accounted for 67.0 percent of the ADEs, while 6.6 percent of the hospitalizations were attributed to Beers-criteria potentially-inappropriate medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2003 Beers criteria have been compared to the Screening Tool of Older Person's Prescriptions (STOPP), another tool for identifying inappropriate prescribing, in terms of their correlation with ADEs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. STOPP and Beers criteria overlapped in several areas, but earlier versions of the Beers criteria used in this comparison contained some drugs no longer in common use, and STOPP includes consideration of drug-drug interactions and duplication of drugs within a class. In two studies, STOPP identified a significantly-higher proportion of older people requiring hospitalization as a result of a medication-related adverse event than did the 2003 Beers criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Health Care Financing Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Health Care Financing Administration (now called Centers for Medicare and Medicaid Services) drug utilization review criteria target eight prescription drug classes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , calcium channel blockers, angiotensin-converting enzyme inhibitors, H-2 receptor antagonists, NSAIDs, benzodiazepines, antipsychotics, and antidepressants) and focus on four types of prescribing problems (inappropriate dosage, inappropriate duration of therapy, duplication of therapies, and potential for drug-drug interactions). In one study, 19 percent of 2508 community dwelling older adults were using one or more medications inappropriately; NSAIDs and benzodiazepines were the drug classes with the most potential problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessing Care of Vulnerable Elders (ACOVE) project",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another expert panel has identified quality indicators for appropriate medication use as part of the Assessing Care of Vulnerable Elders (ACOVE) project [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. These indicators begin with practical suggestions on how to improve prescribing practices:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Document the indication for a new drug therapy",
"     </li>",
"     <li>",
"      Educate patients on the benefits and risks associated with the use of a new therapy",
"     </li>",
"     <li>",
"      Maintain a current medication list",
"     </li>",
"     <li>",
"      Document response to therapy",
"     </li>",
"     <li>",
"      Periodically review the ongoing need for a drug therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, these indicators specify drug therapies that either should not be prescribed for older adults or that warrant careful monitoring after they have been initiated (",
"    <a class=\"graphic graphic_table graphicRef73834 \" href=\"mobipreview.htm?9/43/9918\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     UNDERUTILIZATION OF APPROPRIATE MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much attention has been paid to over-prescribing for older adults; under-prescribing appropriate medications is also of concern. Prescribing strategies that seek to simply limit the overall number of drugs prescribed to older adults in the name of improving quality of care may be seriously misdirected.",
"   </p>",
"   <p>",
"    Clinicians may be better at avoiding over-prescribing of inappropriate drug therapies than at prescribing indicated drug therapies. As an example, one study of older adults (n = 372) in two managed care organizations found that 50 percent had not been prescribed some recommended therapy, while only 3 percent were prescribed medications classified as inappropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/56\">",
"     56",
"    </a>",
"    ]. However, under- and overutilization of medications were equally prevalent in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/57\">",
"     57",
"    </a>",
"    ]. In a VA outpatient population, mean age 75 years (n = 196), inappropriate medications were documented for 65 percent and medication underuse for 64 percent; simultaneous under and overutilization occurred in 42 percent of patients.",
"   </p>",
"   <p>",
"    However, it should also be recognized that determination of \"under-prescribing\" is based on guidelines that address individual disease entities, while most geriatric patients have multiple conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, a patient with a myocardial infarction, history of diabetes, and elevated lipids would require a beta-blocker, ACE inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , statin, and a hypoglycemic medication. Accordingly, many older adults need to take six or more essential medications. In this context, clinicians may make informed decisions to \"underprescribe,\" to foster compliance with essential medications, limit drug interactions, and prioritize health benefits for active treatment of serious conditions over preventive therapies or conditions that have less impact on quality of life.",
"   </p>",
"   <p>",
"    Factors leading to unintended underutilization include clinicians not recognizing medication benefit in the older population, affordability, and dose availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medication effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of drug effectiveness specifically often exclude the geriatric population, due to concerns with comorbidities and side effects causing difficulty in interpretation of study results. Therefore, the benefit of treatment for older adults, especially for preventive purposes, may not be established or may not be recognized by prescribing clinicians. As an example, in a study of statin use for secondary prevention in patients over age 66, the likelihood of being prescribed statin therapy declined 6.4 percent for every year of age; overall, only 19 percent of patients in this high risk population had been prescribed a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Affordability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prescription may be written but not filled, or filled and not taken regularly, due to financial considerations. This may be a particular problem in countries where there is no universal insurance coverage for drug therapy for older adults.",
"   </p>",
"   <p>",
"    Enhanced drug coverage for older adults can be a powerful incentive to improve the use of beneficial therapies. A comparison of two groups of Medicare patients, as an example, found that statin use was 4.1 percent in patients without drug coverage and 27 percent in those with drug benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/59\">",
"     59",
"    </a>",
"    ]. Significant utilization differences between insured and uninsured patients were seen even for the use of inexpensive medications such as beta-blockers and nitrates.",
"   </p>",
"   <p>",
"    Cost-related medical noncompliance affected almost 30 percent of disabled Medicare enrollees in 2004, and noncompliance rates were significantly higher for patients with multiple comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information on the affordability of medications can be found elsewhere in UpToDate. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"     \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dose availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older individuals often require lower than usual doses of medications, especially at initiation. If medications are not readily available in prescribed doses, the need to split tablets may make it more difficult for patients to take beneficial drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVERSE DRUG EVENTS (ADES)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors in older individuals contribute to their increased risk for developing a drug-related problem. These include frailty, coexisting medical problems, memory issues, and use of multiple prescribed and non-prescribed medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-related hospitalizations account for 2.4 to 6.5 percent of all medical admissions in the general population; the proportion is much higher for older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. In the United States, it is estimated that annually from 2007 to 2009 there were 99,628 emergency hospitalizations for adverse drug events in individuals 65 years and older, with two-thirds due to unintentional overdoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/50\">",
"     50",
"    </a>",
"    ]. A meta-analysis found a fourfold increase in the rate of hospitalization related to adverse drug events in older adults compared with younger adults (16.6 versus 4.1 percent); it was estimated that 88 percent of the ADE hospitalizations among older adults were preventable, compared with 24 percent among young persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse drug reactions (ADRs) are noxious responses to drugs used in usual doses for treatment or prevention of disease. Adverse drug events (ADEs) are any injury that occurs from a drug, including noxious responses, drug administration errors, and any other circumstances that lead to an injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prescribing cascades",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescribing cascades occur when a new drug is prescribed to treat symptoms arising from an unrecognized adverse drug event related to an existing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/22\">",
"     22",
"    </a>",
"    ]. The patient is then at risk for developing additional adverse drug events related to the new and potentially unnecessary treatment (",
"    <a class=\"graphic graphic_table graphicRef74478 \" href=\"mobipreview.htm?20/55/21371\">",
"     table 5",
"    </a>",
"    ). Older adults with chronic disease and multiple drug therapies are at particular risk for prescribing cascades.",
"   </p>",
"   <p>",
"    Drug-induced symptoms in an older person can be easily misinterpreted as indicating a new disease or can be attributed to the aging process itself rather than the drug therapy. This misinterpretation is particularly likely when the drug-induced symptoms are indistinguishable from illnesses that are common in older persons. Selected examples of prescribing cascades are described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the best recognized examples of a prescribing cascade relates to the initiation of anti-Parkinson therapy for symptoms arising from use of drugs such as antipsychotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/67-69\">",
"       67-69",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/70\">",
"       70",
"      </a>",
"      ]. The anti-Parkinson drugs can then lead to new symptoms, including orthostatic hypotension and delirium.",
"      <br/>",
"      <br/>",
"      In a case-control study of 3512 Medicaid patients (age 65 to 99 years), patients who had received an antipsychotic medication in the preceding 90 days were 5.4 times more likely to be prescribed anti-Parkinson therapy than patients who had not received an antipsychotic (95% CI 4.8-6.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some prescribing cascades may be less obvious, especially for drugs whose adverse events are not as commonly recognized. As an example, cholinesterase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"       rivastigmine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"       galantamine",
"      </a>",
"      ) are commonly used for the management of dementia symptoms in older adults. The adverse events associated with these drugs can be viewed as the reverse of those that might be expected with anticholinergic therapies. Accordingly, while anticholinergic therapies may cause constipation and urinary retention, cholinesterase inhibitors may cause diarrhea and urinary incontinence. A prescribing cascade occurs when the prescription of a cholinesterase inhibitor is followed by a prescription for an anticholinergic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/59/10167?source=see_link\">",
"       oxybutynin",
"      </a>",
"      ) to treat incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective cohort study in older adults in Canada (n = 44,884) found that the risk of treatment with an anticholinergic medication for urinary incontinence was greater for patients who had received a cholinesterase inhibitor (adjusted hazard ratio 1.53; 95% CI 1.39-1.72) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/71\">",
"     71",
"    </a>",
"    ]. This study suggests that clinicians should consider the possible contributing role of cholinesterase inhibitors in new-onset or worsening urinary incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults are particularly vulnerable to drug-drug interactions because they often have multiple chronic medical conditions requiring multiple drug therapies. The risk of an adverse event due to drug-drug interactions is substantially increased when multiple drugs are taken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/72-76\">",
"     72-76",
"    </a>",
"    ]. As an example, the risk of bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is increased with coadministration of selective and non-selective NSAIDs, SSRIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , lipid-lowering agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case control study from Canada evaluated hospitalizations for drug-related toxicity in a population of older patients who had received one of three common drug therapies used in older adults:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , or ACE inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/76\">",
"     76",
"    </a>",
"    ]. Hospitalization for hypoglycemia was six times more likely in patients who had received co-trimoxazole. Digoxin toxicity was 12 times more likely for patients who had been started on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    . Hyperkalemia was 20 times more likely for patients who were treated with a potassium sparing diuretic.",
"   </p>",
"   <p>",
"    Care must be taken when prescribing any medication, especially for the older individual, to review existing medications and consider potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dose-related adverse drug events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse drug events are often dose-related. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study from the 1980's related risk of hip fracture in a Medicaid population with use and dose of psychotropic drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/77\">",
"       77",
"      </a>",
"      ]. A dose-related effect was seen for use of long half-life hypnotic-anxiolytics, tricyclic antidepressants, or neuroleptic therapy, and hospitalization for hip fracture.",
"     </li>",
"     <li>",
"      A study of people 65 years and older in Quebec (n &gt;250,000) found that more than a quarter (27.6 percent) were dispensed at least one prescription for a benzodiazepine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/78\">",
"       78",
"      </a>",
"      ]. The risk of injury was dose related for some benzodiazepines (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/50/10022?source=see_link\">",
"       oxazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/3/27703?source=see_link\">",
"       flurazepam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4679?source=see_link\">",
"       chlordiazepoxide",
"      </a>",
"      ) though not for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Dose of benzodiazepine, but not elimination half life, was related to risk for hip fracture in a case control study of adults aged 55 years and older from the Netherlands [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common cause of dose-related adverse events in older adults is failure to properly adjust doses for renal insufficiency. Renal impairment becomes more common with advancing age. For patients with stable renal function, creatinine clearance can be estimated according to published formulas which factor age into the calculation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/8/16513?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Because of decreased muscle mass in older adults, however, serum creatinine levels may not adequately reflect renal function; many older patients with a normal creatinine nonetheless have modestly impaired renal function. In one study, 40 percent of almost 10,000 older adults living in long-term care were found to have renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/79\">",
"     79",
"    </a>",
"    ]. In a community population over age 65 in France, the prevalence of renal insufficiency (estimated glomerular filtration rate [eGFR] &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.73m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was 13.7 percent using the MDRD equation and 36.9 percent using the Cockcroft-Gault formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing guidelines for decreased creatinine clearance are available to calculate dose adjustments for medications that are cleared through the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/81\">",
"     81",
"    </a>",
"    ]. The list of medications is long, and includes many antibiotics. In a community population, 52 percent of adults over age 65 with mild renal insufficiency were taking medications that required dose adjustment for low GFR; antihypertensives, fibrates,",
"    <span class=\"nowrap\">",
"     sedative/hypnotic,",
"    </span>",
"    and anxiolytic medications accounted for most of these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/80\">",
"     80",
"    </a>",
"    ]. The drug database (Lexi-Comp) available through UpToDate includes appropriate dose adjustments for renal function and for older adults, and can be accessed by searching on any individual drug. As a general rule, the initial dose for starting medications in older adults should be significantly reduced, and titrated up as tolerated by monitoring side effects or drug levels.",
"   </p>",
"   <p>",
"    Decision aids have been moderately effective in decreasing the percentage of in-hospital prescriptions written with inappropriate adjustments for renal status (46 percent to 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adverse drug events in long-term care setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term care residents are at a particularly high risk for developing adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/83\">",
"     83",
"    </a>",
"    ]. The average US nursing home resident uses seven to eight different medications each month, and about one-third of residents have monthly drug regimens of nine or more medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of adverse drug events in two large academic long-term care facilities in the United States and Canada found 815 ADEs occurring during 8336 resident months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/83\">",
"     83",
"    </a>",
"    ]. The overall rate of adverse drug events was 9.8 per 100 resident&ndash;months; 42 percent of the ADEs were deemed preventable. Of the more serious adverse events, 61 percent were deemed preventable. The more serious the adverse event, the more likely it was to be considered potentially preventable. These rates were approximately four-times higher than had been previously reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/85\">",
"     85",
"    </a>",
"    ], but may reflect the better documentation of ADEs at these institutions.",
"   </p>",
"   <p>",
"    Preventable adverse drug events were most frequently associated with atypical antipsychotics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy (",
"    <a class=\"graphic graphic_table graphicRef71281 \" href=\"mobipreview.htm?0/49/796\">",
"     table 6",
"    </a>",
"    ). Neuropsychiatric events (confusion, oversedation, delirium), hemorrhagic, and gastrointestinal events were the most frequent types of ADEs in the long term care facilities studied (",
"    <a class=\"graphic graphic_table graphicRef72518 \" href=\"mobipreview.htm?40/13/41180\">",
"     table 7",
"    </a>",
"    ). In a 12-month observational study of 490 long-term care residents taking warfarin in 25 nursing homes, there were 720 adverse drug events (625 minor, 82 serious, and 13 life-threatening); 57 percent of the serious events were considered preventable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Atypical antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical antipsychotic medications, used for the management of the behavioral and psychological symptoms of dementia, are among the drugs most frequently associated with adverse events in long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/83\">",
"     83",
"    </a>",
"    ]. In particular, psychotropic medications are associated with an increased risk for falls. In one meta-analysis of patients age 60 or older, the odds ratio for any psychotropic use among patients who had one or more falls was 1.73 (95% CI 1.52-1.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited evidence to support the efficacy of these agents for management of behavioral and psychological symptoms in older adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Antipsychotic drugs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonetheless, use of antipsychotic medications in long term care facilities is widespread. A study of 19,780 older adults with no history of major psychosis prior to long-term care admission found that antipsychotic therapy was prescribed for 17 percent within 100 days of their long term care admission, and for 24 percent within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/88\">",
"     88",
"    </a>",
"    ]. A study of 485 nursing homes in Canada found that there was about a three-fold variation in antipsychotic prescribing, not related to clinical factors, between high- and low-prescribing facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A public health advisory warning issued from the FDA warns of fatal adverse events in demented patients treated with atypical antipsychotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. Data from 17 trials of older adult patients with dementia have shown that those treated with atypical antipsychotic therapy were 1.6 to 1.7 times more likely to die than those given placebo therapy. Similar concerns have been raised for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and other conventional antipsychotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. A retrospective comparison of patients with dementia who were newly treated with atypical antipsychotics, compared to no antipsychotics, found an increased risk of death at 30 and 180 days for the treated group (at 30 days, adjusted HR 1.55, 95% CI 1.15-2.07) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/95\">",
"     95",
"    </a>",
"    ]. Mortality was further increased, again by a factor of 1.55, for patients receiving conventional antipsychotics compared to atypical antipsychotics. These data point to the need to rethink the role of these therapies in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1053332112\">",
"    <span class=\"h2\">",
"     Predicting adverse drug reactions",
"    </span>",
"   </p>",
"   <p>",
"    A tool has been developed to identify older adult patients at increased risk for an ADR in hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/96\">",
"     96",
"    </a>",
"    ]. The tool, based on logistic regression analysis from a group of Italian patients mean age 78, and validated in a separate European cohort, found that the number of drugs prescribed and prior history of an ADR were the strongest predictors for a subsequent ADR. Compared to those receiving five or fewer medications, the risk of ADR was approximately doubled (OR 1.9, 95% CI 1.35-2.68) for those prescribed five to seven medications, and was fourfold (OR 4.07, CI 2.93-5.65) for those receiving eight or more medications. Other variables incorporated in this tool are the presence of four or more comorbid conditions, heart failure, liver disease, or renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Preventing adverse drug events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of preventable adverse drug events is a significant concern. Inappropriate ordering and inadequate monitoring are the most common errors in preventable adverse drug events. Errors in transcription, dispensing, and administration are less commonly identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications that are commonly implicated in preventable adverse drug events are not generally those identified by widely utilized \"bad drug\" lists. \"Good drugs\" prescribed in an inappropriate manner may be far more problematic. When drugs do cause problems, it is often because they are prescribed, dosed, or monitored inappropriately.",
"   </p>",
"   <p>",
"    Prevention of adverse drug events in the hospital setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30521?source=see_link\">",
"     \"Prevention of adverse drug events in hospitals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Long-term care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced surveillance and reporting systems for adverse drug events occurring in the nursing home setting are needed. Computerized order entry in the hospital setting has been shown to reduce serious medication errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/97\">",
"     97",
"    </a>",
"    ]. A computer-based decision aid reduced in-hospital inappropriate dosing of psychotropic medications for geriatric inpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/98\">",
"     98",
"    </a>",
"    ]. However, a randomized trial of computerized order entry with clinical decision support in 29 resident care units at two longterm care facilities in Canada did not affect the rate of adverse drug events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Community care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient errors in medication adherence are a significant contributor to adverse drug events for older patients living in the community, accounting for 21 percent of preventable ADEs in a large ambulatory Medicare population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/100\">",
"     100",
"    </a>",
"    ]. Patient errors occurred more frequently in patients who were regularly taking three or more medications, compared to those taking two or fewer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practical recommendations to reduce medical errors in the community have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/102-107\">",
"     102-107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain an accurate list of all medications that a patient is currently using. This list should include the drug name (generic and brand), dosage, frequency, route, and indication.",
"     </li>",
"     <li>",
"      Advise periodic \"brown bag check-ups.\" Instruct patients to bring all pill bottles to each medical visit; bottles should be checked against the medication list.",
"     </li>",
"     <li>",
"      Patients should be made aware of potential drug confusions: sound-alike names, look-alike pills, and combination medications.",
"     </li>",
"     <li>",
"      Patients should be informed of both generic and brand names, including spelling, as well as the reasons for taking their medications. This may prevent unnecessary confusion when drugs are inconsistently labeled. As an example, a patient may be unaware that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      (generic) and Lanoxin (brand) are the same therapy.",
"     </li>",
"     <li>",
"      Medication organizers that are filled by the patient, family member, or caregiver, can facilitate compliance with drug regimens. Blister packs for individual drugs, prepared by the pharmacist, can also be helpful in ensuring that patients take their medications correctly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Community pharmacists are an important resource and can play a key role in working with older adults to reduce medication errors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Transitions in care settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transitions in care, between hospital and nursing home, or institutional setting and home, are a common source of medication errors and confusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One Canadian multisite study found that 25 percent of 325 older adults experienced an ADE after discharge home from the hospital; half of these ADEs were considered preventable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Changes in medication (different dose, discontinued therapies, additional therapies) were identified in 45 of 50 patients discharged from a geriatric ward in the UK within 6 to 14 days of discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/103\">",
"       103",
"      </a>",
"      ]. Of particular concern is discharge of older patients with new prescriptions for benzodiazepines that were initiated in the hospital, leading to unplanned chronic benzodiazepine use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Attending physicians from an academic medical center reported that they believed 89 percent of their discharged patients (n = 99) understood potential side effects of their medications; 58 percent of those discharged patients reported that they understood this information [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adverse drug events attributed to medication changes occurred in 20 percent of patients on transfer from hospital to a nursing home, occurring most commonly for patients being readmitted to the nursing home (12 of 14 events) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frail older people are often found to be on unnecessary drug regimens at the time of hospital discharge. Among 384 older veterans, 44 percent were found to have at least one unnecessary drug therapy at the time of discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/111\">",
"       111",
"      </a>",
"      ]. Factors contributing to this include multiple prescribers, \"routine\" medications for hospitalization such as antacids or stool softeners, and being on nine or more drug therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Effort must be made to improve communication in \"hand-offs\" of patient care during transitions in care setting. This is particularly true when the physician responsible for the patient in the hospital is not the same as the physician providing the patient's longitudinal care. Accurate medication lists, direct communications between providers, and a thorough review of all medications at the time of care transition for appropriateness and intended duration of treatment, are steps that should be taken to avoid ADEs. Whenever possible, the number of prescribing physicians for an individual patient should be limited, as the number of prescribing physicians is an independent risk factor for ADEs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     A STEPWISE APPROACH TO PRESCRIBING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presented below is one systematic approach to improving prescribing practices when managing older adults. Other systematic approaches have been described incorporating similar elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/113\">",
"     113",
"    </a>",
"    ]. Regardless of the sequence of steps, what is essential in prescribing is to continually reappraise the patient&rsquo;s medication regimen in light of his or her current clinical status, goals of care, and the potential",
"    <span class=\"nowrap\">",
"     risks/benefits",
"    </span>",
"    of each medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18186195\">",
"    <span class=\"h2\">",
"     Review current drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic evaluation of a patient's drug regimen is an essential component of medical care for an older person. Such a review may indicate the need for changes to prescribed drug therapy. These changes may include discontinuing a therapy prescribed for an indication that no longer exists, substituting a therapy with a potentially safer agent, changing drug dosage, or adding a new medication (",
"    <a class=\"graphic graphic_table graphicRef52450 \" href=\"mobipreview.htm?2/38/2667\">",
"     table 8",
"    </a>",
"    ). A medication review should consider whether a change in patient status (eg renal or liver function) might necessitate dosing adjustment, the potential for drug-drug interaction, whether patient symptoms might reflect a drug side effect, or whether the regimen could be simplified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a survey of Medicare beneficiaries, more than 30 percent of patients reported they had not talked with their doctor about their different medications in the previous 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/115\">",
"     115",
"    </a>",
"    ]. Ideally, the clinician should ask the patient to bring to the visit all of the bottles of pills that they are using. Patients may not consider over-the-counter products, ointments, vitamins, ophthalmic preparations, or herbal medicines to be drug therapies and need to be specifically told to bring these to the visit.",
"   </p>",
"   <p>",
"    Unintended medication discrepancies, particularly likely to occur at the time of hospital admissions, are a common source for medication errors. As an example, one study evaluated 151 patients (average age 77 years) admitted to general internal medicine clinical teaching units and found discrepancies in more than half between admission medication orders and the patient's usual drug therapies as identified by a medication history interview [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/116\">",
"     116",
"    </a>",
"    ]. Most discrepancies involved unintentional omission of a maintenance medication and more than a third of these discrepancies had the potential to cause moderate harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Discontinue unnecessary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are often reluctant to stop medications, especially if they did not initiate the treatment and the patient seems to be tolerating the therapy. Sometimes, this exposes the patient to the risks for an adverse event with limited therapeutic benefit. A common example is the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in older adults, often prescribed for indications that have not been well documented. Renal impairment or temporary dehydration may predispose older adults to digoxin toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/117\">",
"     117",
"    </a>",
"    ]. Although digoxin therapy can be safely discontinued in selected nursing home residents, it is important to recognize that discontinuation in patients with impaired systolic function can have a detrimental effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to discontinue medication is determined in part by the goals of care for that patient and the risks of adverse effects for that patient. Targets for treatment, based on outcomes evidence from studies in younger patients, may not be appropriate for older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/23\">",
"     23",
"    </a>",
"    ]; thus clinical guidelines not targeted to older patients may foster overly-aggressive goals for management of hypertension or diabetes in the older adult population.",
"   </p>",
"   <p>",
"    One approach to assessing whether a drug is truly necessary for a given patient is presented in an algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/119\">",
"     119",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_algorithm graphicRef61655 \" href=\"mobipreview.htm?25/5/25695\">",
"     algorithm 1",
"    </a>",
"    ). In a feasibility study performed in a cohort of 70 community-dwelling patients seen for geriatric assessment, implementation of this algorithm led to recommendations to discontinue 58 percent of the medications they had been taking. Eighty-one percent of these medications were discontinued, 2 percent were restarted, and no significant adverse events were attributable to discontinuation over 13 month follow-up.",
"   </p>",
"   <p>",
"    Some preventive and other therapies may no longer be beneficial to patients with short life expectancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/25\">",
"     25",
"    </a>",
"    ]. The appropriateness of these therapies should be reconsidered when other medical conditions develop that impact a patient's long-term prognosis, unless the therapies are thought to increase comfort.",
"   </p>",
"   <p>",
"    There are limited studies about how best to withdraw medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/24\">",
"     24",
"    </a>",
"    ]. It is reasonable to gradually taper off most medications to minimize withdrawal reactions and to allow symptom monitoring, unless dangerous signs or symptoms indicate a need for abrupt medication withdrawal. Certain common drugs require tapering, including beta blockers, opioids, barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and antidepressants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Consider adverse drug events for any new symptom",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before adding a new therapy to the patient's drug regimen, clinicians should carefully consider whether the development of a new medical condition could be linked to an existing drug therapy. Many prescribing cascade scenarios have been identified (",
"    <a class=\"graphic graphic_table graphicRef74478 \" href=\"mobipreview.htm?20/55/21371\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Prescribing cascades'",
"    </a>",
"    above.)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Consider nonpharmacologic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some conditions in older adults may be amenable to lifestyle modification in lieu of pharmacotherapy. The Trial of Nonpharmacologic Interventions in the Elderly (TONE) demonstrated that weight loss and reduced sodium intake could allow discontinuation of antihypertensive medication in about 40 percent of the intervention group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Lifestyle modifications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Substitute with safer alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;When drug therapy is indicated for the older patient, it may be possible to substitute a safer alternative for the current regimen. As an example, in treatment of non-inflammatory arthritis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may provide adequate pain relief and be a safer alternative to NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/122\">",
"     122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .) Numerous studies have documented adverse events associated with NSAID use in older persons, including gastrointestinal bleeds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/123\">",
"     123",
"    </a>",
"    ], renal impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/124\">",
"     124",
"    </a>",
"    ], and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Reduce the dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many adverse drug events are dose-related. When prescribing drug therapies it is important to use the minimal dose required to obtain clinical benefit. As an example, one study evaluated the relationship between prescribing of the newer atypical antipsychotic therapies (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) and the development of parkinsonism in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/68\">",
"     68",
"    </a>",
"    ]. Relative to those dispensed a low-dose, those dispensed a high-dose were more than twice as likely to develop parkinsonism (HR 2.07, 95% CI 1.42-3.02). As another example, one case-control study in patients over age 70 who received thyroid supplementation identified a correlation between risk of fracture and dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    , indicating the importance of testing for thyroid levels in this population and adjusting the dose accordingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5258946\">",
"    <span class=\"h2\">",
"     Simplify the dosing schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;When multiple medications are required, greater regimen complexity will increase the likelihood of poor compliance or confusion with dosing. Older adults, and particularly those with low health literacy, are not able to efficiently consolidate prescription regimens to optimize a dosing schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/127\">",
"     127",
"    </a>",
"    ]. The Institute of Medicine has proposed a standardized schedule for specifying medication dosing (morning, noon, evening, bedtime), recognizing that 90 percent of prescriptions are taken four or fewer times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/0/30730/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Prescribe beneficial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fewer-the-better approach to drug therapy in older adults is often not the best response to optimizing drug regimens. Avoiding medications with known benefits to minimize the number of drugs prescribed is inappropriate. Patients must be informed about the reason to initiate a new medication, and what the expected benefits are.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/34/32290?source=see_link\">",
"       \"Patient information: Taking medicines when you're older (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The possibility of an adverse drug event (ADE) should always be borne in mind when evaluating an older adult; any new symptom should be considered drug-related until proven otherwise. Pharmacokinetic changes lead to increased plasma drug concentrations and pharmacodynamic changes lead to increased drug sensitivity in older adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians must be alert to the use of herbal and dietary supplements by older patients, who may not volunteer this information and are prone to drug-drug interactions related to these supplements. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Herbal and dietary supplements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various criteria sets exist identifying medications that should not be prescribed, or should be prescribed with caution, in older adults. Compliance with these lists of medications to be avoided is suboptimal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Inappropriate medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians also underprescribe medications, such as statins, that could provide benefit for older adults. Clinicians may be better at avoiding overprescribing of inappropriate drug therapies than at prescribing indicated drug therapies. Patient financial constraints and unavailability of prescribed doses may contribute to medication underutilization. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Underutilization of appropriate medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse drug events result in four times as many hospitalizations in older, compared with younger, adults. Prescribing cascades, drug-drug interactions, and inappropriate drug doses are causes of preventable ADEs. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse drug events (ADEs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse drug events are a particular problem for nursing home residents; atypical antipsychotic medications and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      are the most common drugs involved in ADEs in this population. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adverse drug events in long-term care setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A step-wise approach to prescribing for older adults should include: periodic review of current drug therapy; discontinuing unnecessary medications; considering non-pharmacologic alternative strategies; considering safer alternative medications; using the lowest possible effective dose; including all necessary beneficial medications. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'A stepwise approach to prescribing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/1\">",
"      Cho S, Lau SW, Tandon V, et al. Geriatric drug evaluation: where are we now and where should we be in the future? Arch Intern Med 2011; 171:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/2\">",
"      Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/3\">",
"      Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/4\">",
"      Pomara N, Stanley B, Block R, et al. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. Psychopharmacology (Berl) 1984; 84:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/5\">",
"      Pomara N, Stanley B, Block R, et al. Increased sensitivity of the elderly to the central depressant effects of diazepam. J Clin Psychiatry 1985; 46:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/6\">",
"      Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/7\">",
"      Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/8\">",
"      Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/9\">",
"      Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/10\">",
"      Kelly JP, Kaufman DW, Kelley K, et al. Recent trends in use of herbal and other natural products. Arch Intern Med 2005; 165:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/11\">",
"      Nahin RL, Fitzpatrick AL, Williamson JD, et al. Use of herbal medicine and other dietary supplements in community-dwelling older people: Baseline data from the ginkgo evaluation of memory study. J Am Geriatr Soc 2006; 54:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/12\">",
"      Nahin RL, Pecha M, Welmerink DB, et al. Concomitant use of prescription drugs and dietary supplements in ambulatory elderly people. J Am Geriatr Soc 2009; 57:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/13\">",
"      Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993; 328:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/14\">",
"      Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/15\">",
"      Wold RS, Lopez ST, Yau CL, et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc 2005; 105:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/16\">",
"      Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/17\">",
"      Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/18\">",
"      Ferner RE, Aronson JK. Communicating information about drug safety. BMJ 2006; 333:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/19\">",
"      Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351:2870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/20\">",
"      Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/21\">",
"      Lai SW, Liao KF, Liao CC, et al. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine (Baltimore) 2010; 89:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/22\">",
"      Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997; 315:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/23\">",
"      Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/24\">",
"      Steinman MA, Hanlon JT. Managing medications in clinically complex elders: \"There's got to be a happy medium\". JAMA 2010; 304:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/25\">",
"      Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/26\">",
"      Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med 2009; 361:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/27\">",
"      Givens JL, Jones RN, Shaffer ML, et al. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010; 170:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/28\">",
"      McLeod PJ, Huang AR, Tamblyn RM, Gayton DC. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997; 156:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/29\">",
"      Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/30\">",
"      Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/31\">",
"      Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163:2716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/32\">",
"      Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001; 286:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/33\">",
"      Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/34\">",
"      Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001; 135:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/35\">",
"      Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med 2007; 167:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/36\">",
"      Hilmer SN, Mager DE, Simonsick EM, et al. Drug burden index score and functional decline in older people. Am J Med 2009; 122:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/37\">",
"      Wilson NM, Hilmer SN, March LM, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc 2011; 59:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/38\">",
"      Carri&egrave;re I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/39\">",
"      Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/40\">",
"      Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/41\">",
"      Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/42\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/43\">",
"      Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/44\">",
"      Lane CJ, Bronskill SE, Sykora K, et al. Potentially inappropriate prescribing in Ontario community-dwelling older adults and nursing home residents. J Am Geriatr Soc 2004; 52:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/45\">",
"      Fialov&aacute; D, Topinkov&aacute; E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/46\">",
"      Rochon PA, Lane CJ, Bronskill SE, et al. Potentially inappropriate prescribing in Canada relative to the US. Drugs Aging 2004; 21:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/47\">",
"      Lau DT, Kasper JD, Potter DE, et al. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med 2005; 165:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/48\">",
"      Jano E, Aparasu RR. Healthcare outcomes associated with beers' criteria: a systematic review. Ann Pharmacother 2007; 41:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/49\">",
"      Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007; 147:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/50\">",
"      Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/51\">",
"      Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008; 37:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/52\">",
"      Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008; 46:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/53\">",
"      Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011; 171:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/54\">",
"      Shekelle PG, MacLean CH, Morton SC, Wenger NS. Acove quality indicators. Ann Intern Med 2001; 135:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/55\">",
"      Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007; 55 Suppl 2:S373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/56\">",
"      Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004; 140:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/57\">",
"      Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006; 54:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/58\">",
"      Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/59\">",
"      Federman AD, Adams AS, Ross-Degnan D, et al. Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease. JAMA 2001; 286:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/60\">",
"      Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Arch Intern Med 2006; 166:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/61\">",
"      Rochon PA, Anderson GM, Tu JV, et al. Age- and gender-related use of low-dose drug therapy: the need to manufacture low-dose therapy and evaluate the minimum effective dose. J Am Geriatr Soc 1999; 47:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/62\">",
"      Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007; 370:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/63\">",
"      Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/64\">",
"      Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/65\">",
"      Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/66\">",
"      Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/67\">",
"      Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995; 99:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/68\">",
"      Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005; 165:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/69\">",
"      Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/70\">",
"      Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995; 274:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/71\">",
"      Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005; 165:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/72\">",
"      Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/73\">",
"      Juurlink DN, Mamdani MM, Kopp A, et al. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004; 52:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/74\">",
"      Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/75\">",
"      Battistella M, Mamdami MM, Juurlink DN, et al. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/76\">",
"      Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/77\">",
"      Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/78\">",
"      Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/79\">",
"      Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 2004; 65:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/80\">",
"      Breton G, Froissart M, Janus N, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study. Nephrol Dial Transplant 2011; 26:2852.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff GR, Berns JS, Brier ME, et al.. Drug prescribing in renal failure: Dosing guidelines for adults, 4th ed, American College of Clinicians, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/82\">",
"      Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001; 286:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/83\">",
"      Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/84\">",
"      Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from the 1997 medicare current beneficiary survey and the 1996 medical expenditure survey. J Am Geriatr Soc 2005; 53:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/85\">",
"      Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/86\">",
"      Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med 2007; 120:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/87\">",
"      Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999; 47:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/88\">",
"      Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004; 52:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/89\">",
"      Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167:676.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA MedWatch Safety Alert: RISPERDAL(risperidone), 2003. Available at: www.fda.gov/medwatch/SAFETY/2003/safety03.htm#risper (Accessed on February 09, 2006).",
"    </li>",
"    <li>",
"     www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=27#6 (Accessed on February 09, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/92\">",
"      Lenzer J. FDA warns about using antipsychotic drugs for dementia. BMJ 2005; 330:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/93\">",
"      Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/94\">",
"      Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/95\">",
"      Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/96\">",
"      Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med 2010; 170:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/97\">",
"      Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/98\">",
"      Peterson JF, Kuperman GJ, Shek C, et al. Guided prescription of psychotropic medications for geriatric inpatients. Arch Intern Med 2005; 165:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/99\">",
"      Gurwitz JH, Field TS, Rochon P, et al. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc 2008; 56:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/100\">",
"      Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/101\">",
"      Field TS, Mazor KM, Briesacher B, et al. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc 2007; 55:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/102\">",
"      Forster AJ, Clark HD, Menard A, et al. Adverse events among medical patients after discharge from hospital. CMAJ 2004; 170:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/103\">",
"      Cochrane RA, Mandal AR, Ledger-Scott M, Walker R. Changes in drug treatment after discharge from hospital in geriatric patients. BMJ 1992; 305:694.",
"     </a>",
"    </li>",
"    <li>",
"     Gurwitz J. Case and commentary. Spotlight case. Double Trouble. Medicine, September 2005. Available at: www.webmm.ahrq.gov/case.aspx?caseID=104 (Accessed on March 27, 2006).",
"    </li>",
"    <li>",
"     The Institute for Safe Medication Practices. How to Take Your Medications Safely. Availabe at: file://www.ismp.org/Newsletters/consumer/alerts/Brochure.asp (Accessed on March 27, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/106\">",
"      Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/107\">",
"      Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ 2008; 336:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/108\">",
"      Bell CM, Fischer HD, Gill SS, et al. Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med 2007; 22:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/109\">",
"      Calkins DR, Davis RB, Reiley P, et al. Patient-physician communication at hospital discharge and patients' understanding of the postdischarge treatment plan. Arch Intern Med 1997; 157:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/110\">",
"      Boockvar K, Fishman E, Kyriacou CK, et al. Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 2004; 164:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/111\">",
"      Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc 2005; 53:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/112\">",
"      Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/113\">",
"      Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med 2012; 125:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/114\">",
"      George CJ, Jacobs LG. Geriatrics medication management rounds: a novel approach to teaching rational prescribing with the use of the medication screening questionnaire. J Am Geriatr Soc 2011; 59:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/115\">",
"      Wilson IB, Schoen C, Neuman P, et al. Physician-patient communication about prescription medication nonadherence: a 50-state study of America's seniors. J Gen Intern Med 2007; 22:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/116\">",
"      Cornish PL, Knowles SR, Marchesano R, et al. Unintended medication discrepancies at the time of hospital admission. Arch Intern Med 2005; 165:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/117\">",
"      Forman DE, Coletta D, Kenny D, et al. Clinical issues related to discontinuing digoxin therapy in elderly nursing home patients. Arch Intern Med 1991; 151:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/118\">",
"      Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/119\">",
"      Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med 2010; 170:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/120\">",
"      Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/121\">",
"      Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/122\">",
"      Bradley JD, Brandt KD, Katz BP, et al. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/123\">",
"      Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/124\">",
"      Gurwitz JH, Soumerai SB, Avorn J. Improving medication prescribing and utilization in the nursing home. J Am Geriatr Soc 1990; 38:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/125\">",
"      Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/126\">",
"      Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older adults: nested case-control study. BMJ 2011; 342:d2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/127\">",
"      Wolf MS, Curtis LM, Waite K, et al. Helping patients simplify and safely use complex prescription regimens. Arch Intern Med 2011; 171:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/0/30730/abstract/128\">",
"      Wolf MS, Shekelle P, Choudhry NK, et al. Variability in pharmacy interpretations of physician prescriptions. Med Care 2009; 47:370.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3013 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-37CB1B5951-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30730=[""].join("\n");
var outline_f30_0_30730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICATION USE BY OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Herbal and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      QUALITY OF DRUG PRESCRIBING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18186995\">",
"      POLYPHARMACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INAPPROPRIATE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Anticholinergic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Beers criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Health Care Financing Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessing Care of Vulnerable Elders (ACOVE) project",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      UNDERUTILIZATION OF APPROPRIATE MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medication effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Affordability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dose availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVERSE DRUG EVENTS (ADES)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prescribing cascades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dose-related adverse drug events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Renal impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adverse drug events in long-term care setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Atypical antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1053332112\">",
"      Predicting adverse drug reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Preventing adverse drug events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Long-term care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Community care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Transitions in care settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      A STEPWISE APPROACH TO PRESCRIBING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18186195\">",
"      Review current drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Discontinue unnecessary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Consider adverse drug events for any new symptom",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Consider nonpharmacologic approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Substitute with safer alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Reduce the dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5258946\">",
"      Simplify the dosing schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Prescribe beneficial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3013|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?25/5/25695\" title=\"algorithm 1\">",
"      Medication review",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/2/30765\" title=\"table 1\">",
"      Selected high-risk drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/22/11627\" title=\"table 2\">",
"      Appropriate prescribing in the elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/32/42508\" title=\"table 3\">",
"      Anticholinergic risk scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/43/9918\" title=\"table 4\">",
"      ACOVE quality indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/55/21371\" title=\"table 5\">",
"      Prescribing cascades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/49/796\" title=\"table 6\">",
"      Adverse drug events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/13/41180\" title=\"table 7\">",
"      Frequency adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/38/2667\" title=\"table 8\">",
"      Reviewing medications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/8/16513?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance (measured)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/34/32290?source=related_link\">",
"      Patient information: Taking medicines when you're older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30521?source=related_link\">",
"      Prevention of adverse drug events in hospitals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_0_30731="Calculated risk of natalizumab-related PML";
var content_f30_0_30731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calculated risk of natalizumab-related PML according to currently known risk factors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prior chemotherapy?",
"       </td>",
"       <td class=\"subtitle1\">",
"        Overall risk",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk up to 24 mo therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk after 24 mo therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        JC virus antibody negative",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &sim;1:17,693",
"       </td>",
"       <td>",
"        &sim;1:51,526",
"       </td>",
"       <td>",
"        &sim;1:9629",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &sim;1:6239",
"       </td>",
"       <td>",
"        &sim;1:18,171",
"       </td>",
"       <td>",
"        &sim;1:3396",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        JC virus antibody positive",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        &sim;1:442",
"       </td>",
"       <td>",
"        &sim;1:1288",
"       </td>",
"       <td>",
"        &sim;1:241",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        &sim;1:177",
"       </td>",
"       <td>",
"        &sim;1:454",
"       </td>",
"       <td>",
"        &sim;1:85",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PML: progressive multifocal leukoencephalopathy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fox RJ, Rudick RA. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78:436. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30731=[""].join("\n");
var outline_f30_0_30731=null;
var title_f30_0_30732="Strength training guideline";
var content_f30_0_30732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of strength-training recommendations for children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Individualization",
"      </td>",
"      <td>",
"       Determined by age; physical, emotional, and cognitive limitations; personal goals and objectives.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Warm-up and cool-down",
"      </td>",
"      <td>",
"       Warm up with 5 to 10 minutes of stretching, aerobic exercise, and no-load or light weight repetitions. Cool down with light aerobic activity.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Specificity",
"      </td>",
"      <td>",
"       A well-rounded general strength training program can meet the needs of most children and adolescents.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" rowspan=\"7\">",
"       Overload",
"      </td>",
"      <td>",
"       <strong>",
"        Choice of exercises:",
"       </strong>",
"       Six to eight exercises that train the major muscle groups (chest, shoulders, back, arms, legs, abdomen, lower back) with appropriate balance between flexors and extensors and between upper and lower body muscle groups.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Order of exercises:",
"       </strong>",
"       Perform large-muscle-mass exercises before small-muscle-mass exercises; complex exercises before simple exercises; multijoint exercises before single-joint exercises.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Load:",
"       </strong>",
"       Select a resistance that allows 6 to 15 repetitions. Initially use a lower load that permits higher repetitions.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Sets:",
"       </strong>",
"       Begin with 1 to 2 sets.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Repetitions:",
"       </strong>",
"       6 to 15 repetitions of each exercise per set.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Rest:",
"       </strong>",
"       1 to 3 minutes between sets.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Frequency:",
"       </strong>",
"       2 to 3 days per week.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Adaptation",
"      </td>",
"      <td>",
"       Strength gains can occur in children without significant enlargement of skeletal muscle mass. Strength training increases the number of motor units recruited and improves the coordinated recruitment of motor units, the firing rate or firing pattern of activated motor neurons, and coordination. Increased neural response may facilitate injury prevention in other sports and activities of daily living. During adolescence, strength training results in neurological adaptations, as well as hypertrophy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Progression",
"      </td>",
"      <td>",
"       Increase variety of the program and introduce new movement patterns and motor skills (coordination, skill technique, balance and stabilization) by adding both single- and multijoint exercises. Increase resistance by 5 to 10 percent when 20 repetitions become easy. Before increasing the number of sets or resistance, participants should be able to correctly demonstrate proper technique. Progress to performing 2 to 3 exercises per muscle group for 1 to 3 sets of 10 to 15 repetitions performed 3 days per week.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30732=[""].join("\n");
var outline_f30_0_30732=null;
var title_f30_0_30733="AED mechanisms";
var content_f30_0_30733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common mechanisms of antiepileptic drug action",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Na+ channels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ca+ channels",
"       </td>",
"       <td class=\"subtitle1\">",
"        K+ channels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inhibitory transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Excitatory transmission",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clobazam",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ezogabine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacosamide",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perampanel&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenobarbital",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiagabine",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigabatrin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +++: primary action; ++: probable action; +: possible action.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30733=[""].join("\n");
var outline_f30_0_30733=null;
var title_f30_0_30734="Normal IgG subclass levels in infants and children";
var content_f30_0_30734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Serum immunoglobulin G (IgG) subclass levels in healthy infants and children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time 0 represents the cord blood values. The means for each age group were obtained from data published by Oxelius.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Immunologic Disorders in Infants and Children (5th Ed), Ochs HD, Stiehm ER, Winkelstein JA (Eds), Elsevier Sanders, Philadelphia 2004. p.394. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30734=[""].join("\n");
var outline_f30_0_30734=null;
var title_f30_0_30735="Actinic prurigo";
var content_f30_0_30735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic prurigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 209px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, excoriated papules are present on the legs of this patient with actinic prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright &copy; 2008 The McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_0_30735=[""].join("\n");
var outline_f30_0_30735=null;
